• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Johnson + Johnson kicks off TECNIS Eyhance Toric II IOL in Europe


According to the company, more than 400 eyes of patients from 12 European countries have been fitted with the TECNIS Eyhance Toric II IOL, with surgeons surveyed noting that their patients are pleased with the results.

Image courtesy of Johnson & Johnson Vision.

Image courtesy of Johnson & Johnson Vision.

Johnson + Johnson Vision announced today it is kicking off the availability of its TECNIS Eyhance Toric II IOL with TECNIS Simplicity Delivery System for the treatment of cataracts patients with astigmatism in Europe.

According to the company, the monofocal lens allows for high-quality vision at both intermediate and far distances1 and is specifically engineered for rotational stability.

The lens allows patients to achieve significantly improved intermediate vision, compared with a standard aspheric monofocal IOL, along with 20/20 distance vision.1

According to Filomena Ribeiro, MD, PhD, FEBO, head director of ophthalmology at Hospital da Luz in Lisbon, Portugal, the haptic design and rotational stability of the TECNIS Eyhance Toric II IOL, has allowed her to offer her patients immediate improvements in their functional vision, while also correcting their astigmatism.

“Having implanted the TECNIS Eyhance Toric II IOL, I can confidently say that this IOL is a game-changer in the monofocal category and in helping my patients get back to spending more time doing what they love,” she said in a statement.

A survey of 17 leading European ophthalmologists found that their patients were satisfied with the lens.2 Meanwhile, more than 79% perceived their patients as being very satisfied with their intermediate and distance vision.2

Additionally, 94% of those surveyed were very satisfied with the handling while implanting the lens, while nearly two thirds rated the overall performance of the lens as excellent compared to other toric IOLs.2

More than 80% also rated the rotational stability of the lens as excellent compared to other toric IOLs. All those surveyed said they were very likely to continue to use the lens in the future.2

Erin McEachren, regional vice president, EMEA, Johnson + Johnson Surgical Vision, said the rollout offers the benefits of its most advanced monofocal IOL to cataract patients with astigmatism.

“It is an important first in Europe for the monofocal IOL category, as today most lenses in this category only correct vision to help patients with cataracts see things at a distance, and therefore do not improve the intermediate vision that is required for many important daily tasks,” McEachren said in a statement. “This is another breakthrough in meeting the ever-changing and evolving needs of our patients across Europe and the world.”



1. DOF2018CT4015 – Clinical evaluation of the TECNIS Eyhance Model ICB00 – 6-month clinical study. Sep 2018. Based on a clinical study, N=134 achieved mean 20/20 monocular pooled distance BCDVA.

2. TECNIS Eyhance Toric II IOL – Survey of 17 surgeons about experiences with DIU. May 2021. REF2021CT4156.

Related Videos
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
EyeCon Co-chair Oluwatosin U. Smith, MD: Passion for Research and Education Drives Her Commitment to Ophthalmology
Dr. SriniVas Sadda Discusses Vision for ARVO as New President: Collaboration, Funding Challenges, and Impact of Annual Meetings
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
ASCRS 2024: ViaLase Updates on Nonincisional Glaucoma Treatment Targeting Trabecular Meshwork
Dr. Neda Nikpoor Shares Practical Techniques to Combat Unconscious Gender Bias and Promote Gender Equality in Ophthalmology
ASCRS 2024: George O. Waring, MD, shares early clinical performance of bilateral Odyssey implantation
ASCRS 2024: Deborah Gess Ristvedt, DO, discusses third-generation trabecular micro-bypass
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
© 2024 MJH Life Sciences

All rights reserved.